Skip to main content
. 2019 Nov 13;5(11):eaax9250. doi: 10.1126/sciadv.aax9250

Fig. 2. Doxorubicin-loaded biodegradable PLGA NPs efficiently assemble onto mouse and human erythrocytes.

Fig. 2

(A) Flow cytometry analysis of assembly of DOX-loaded PLGA NPs to mouse erythrocytes at different NP-to-erythrocyte ratios (left to right: 0:1, 50:1, 200:1, 400:1, and 800:1). (B) Percentage of mouse erythrocytes carrying at least one NP. (C) Nanoparticle binding efficiency and (D) drug dose on mouse erythrocytes at different NP–to–mouse erythrocyte ratios. (E) CLSM and (F) SEM images of mouse erythrocytes with drug-loaded NPs assembled on them. Scale bars in (F), 2 μm. (G) CLSM and (H) SEM images of human erythrocytes with drug-loaded NPs assembled on them. Scale bars in (H), 2 μm. (I) Flow cytometry assay of the assembly of drug-loaded NPs to human erythrocytes at different NP-to-erythrocyte ratios (left to right: 0:1, 200:1, 800:1, and 1600:1). (J) Nanoparticle binding efficiency and (K) drug dose on human erythrocytes at different NP-to-erythrocyte ratios.